|
Veliparib (V) monotherapy after progression on placebo (PL) + carboplatin/paclitaxel (CP) in patients with advanced HER2-negative gBRCA-associated breast cancer: Crossover outcomes and exploratory biomarker analyses in BROCADE3. |
|
|
No Relationships to Disclose |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Daiichi Sankyo; Lilly; MSD; Novartis; Pfizer; Roche/Genentech; Seagen |
|
|
Consulting or Advisory Role - Abbvie; Bright Pink |
Research Funding - Abbvie (Inst); AstraZeneca (Inst); InVitae (Inst); PharmaMar (Inst) |
Travel, Accommodations, Expenses - AstraZeneca |
|
|
Consulting or Advisory Role - Abbvie; AstraZeneca; Lilly; Novartis; Pfizer; Roche; Tesaro |
Speakers' Bureau - AstraZeneca; Lilly; Pfizer; Roche |
Other Relationship - Abbvie |
|
|
Consulting or Advisory Role - Abbvie (Inst); Amgen (Inst); AstraZeneca (Inst); AstraZeneca (Inst); IQvia (Inst); Lilly (Inst); Lilly (Inst); Lilly (Inst); Orion (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Roche (Inst); Sirtex Medical (Inst) |
Research Funding - Roche (Inst) |
Expert Testimony - Abbvie; Ariez Pharma; Ariez Pharma; Biocartis; DNA Prime; Lilly; Novartis; The Planning Shop; TRM Oncology |
Travel, Accommodations, Expenses - Congress Care; DNA Prime; Global Teamwork; Pfizer; Puma Biotechnology; Roche; Roche (Inst); TRM Oncology |
|
|
Consulting or Advisory Role - Pfizer |
Speakers' Bureau - Lilly; Lilly |
Research Funding - Abbvie (Inst); Bristol-Myers Squibb (Inst); G1 Therapeutics (Inst); Horizon Oncology Research (Inst); Novartis (Inst); Pfizer (Inst); Prescient Therapeutics (Inst); Seagen (Inst); TapImmune Inc. (Inst); Tesaro (Inst) |
|
|
Consulting or Advisory Role - AstraZeneca; Eisai; Lilly; Novartis; Pfizer; Puma Biotechnology; Roche |
Research Funding - Abbvie (Inst); Boston Biomedical (Inst) |
|
|
Consulting or Advisory Role - Iridium Therapeutics |
Research Funding - Abbvie; Biocept; MedImmune; Novartis; Pfizer; Puma Biotechnology |
Other Relationship - Immunomedics |
|
|
Consulting or Advisory Role - Abbvie |
|
|
Research Funding - Abbvie (Inst); Bayer (Inst); Lilly (Inst); Novartis (Inst); Pfizer (Inst); Pfizer (Inst); Synthon (Inst) |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
Employment - Abbvie; Abbvie (I) |
Stock and Other Ownership Interests - Abbvie; Abbvie (I) |
|
|
|
Stock and Other Ownership Interests - AbbVie |
|
|
|
Stock and Other Ownership Interests - Abbvie |
|
|
No Relationships to Disclose |